Anzeige
Mehr »
Freitag, 24.10.2025 - Börsentäglich über 12.000 News
Das Comeback des Goldrauschs - diesmal ausgelöst durch eine Währungskrise
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P209 | ISIN: US98943L1070 | Ticker-Symbol:
NASDAQ
23.10.25 | 21:56
1,645 US-Dollar
+0,30 % +0,005
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ZENTALIS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ZENTALIS PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur ZENTALIS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.10.Zentalis to present azenosertib data at cancer therapeutics conference5
01.10.Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)55SAN DIEGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1...
► Artikel lesen
02.09.Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)94SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1...
► Artikel lesen
26.08.Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary4
26.08.Zentalis Pharmaceuticals, Inc. - 8-K, Current Report1
ZENTALIS PHARMACEUTICALS Aktie jetzt für 0€ handeln
06.08.Zentalis Pharmaceuticals, Inc. - 10-Q, Quarterly Report1
01.07.Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)126SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1...
► Artikel lesen
18.06.Aktionäre von Zentalis Pharmaceuticals wählen drei Direktoren bei Jahreshauptversammlung3
18.06.Zentalis Pharmaceuticals, Inc. - 8-K, Current Report2
02.06.Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)84SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1...
► Artikel lesen
02.06.Zentalis Pharmaceuticals, Inc. - 8-K, Current Report1
20.05.Zentalis Pharmaceuticals, Inc. - 8-K, Current Report3
14.05.Zentalis Pharmaceuticals GAAP EPS of -$0.67 misses by $0.041
14.05.Zentalis Pharmaceuticals, Inc. - 10-Q, Quarterly Report1
01.05.Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)153SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1...
► Artikel lesen
28.04.Zentalis Pharmaceuticals, Inc. - 8-K, Current Report1
01.04.Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)153SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1...
► Artikel lesen
26.03.Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates165Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part...
► Artikel lesen
03.03.Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)143SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1...
► Artikel lesen
03.02.Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)159SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule...
► Artikel lesen
Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1